Table 4 Long-term outcomes summary of peri-operative radiotherapy from randomized trial in gastric cancer

Pre-CRT

CAMS/PUMC [8]

RT + S

vs. S

Local advanced gastric cancer.

5y-OS 30.1%

10y-OS 20.26%

–

Proportion of D2 resection: 40%

CROSS [12]

CRT + S

vs. S

Oesophageal or junctional cancer; T1–3N0–1M0(UICC 6th edition).

1y-OS 81%

2y-OS 67%

3y-OS 58%

5y-OS 47%

1y-PFS 71%

2y-PFS 60%

3y-PFS 51%

5y-PFS 44%

Proportion of EGJ 22–26%

POET [13]

CT + CRT + S

vs. CT + S

Adenocarcinoma of EGJ;

T3-T4(UICC 5th edition).

3y-OS 46.7%

5y-OS 39.5%

–

–

Post-CRT

INT-0116 [14]

S + CRT

vs. S

Adenocarcinoma of the stomach or EGJ;

IB ~ IVM0.

3y-OS 50%

3y-RFS 48%

Proportion of D2, D1, D0 resection: 10, 36, 54%;

Proportion of EGJ 7.0%

ARTIST [15]

S + XP + CRT + XP

vs. S + XP

Gastric cancer;

IB-IV(M0) (AJCC 6th edition);

D2 resection.

5y-OS 75%

3y-DFS 78%

–

CALGB 80101 [16]

S + CT + CRT + CT

ECF vs. FU/LV

CRT with FU

Gastric cancer /EGJ;

IB-IV(M0) (AJCC 6th edition).

5y-OS 44%

5y-DFS 37% vs. 39% (FU/ LV: ECF)

Proportion of EGJ 22%

CRITICS [17]

ECC + S + ECC

ECC + S + CRT

Gastric cancer/EGJ;

IB-IVa (AJCC 6th edition).

5y-OS 42%

5-year EFS 38%

Proportion of D2 + D3

< 10%;

Proportion of EGJ 17.1%

ARTIST II [18]

S + CRT

S + S1

S + SOX

Gastric cancer;

Stage II-III;

N+;

D2 resection.

–

3y-DFS 73%

–